Page 22 - Robert Kramer News Today

Shake-Up at Covid Vaccine Manufacturer That Tossed Millions of Doses Emergent BioSolutions’ C.E.O. announced several executive changes but vigorously defended the company, which is on track for record revenues. Production was halted this month at the Emergent plant in Baltimore where up to 15 million doses of Johnson & Johnson vaccine had to be scrapped.Credit...Saul Loeb/Agence France-Presse — Getty Images April 29, 2021 WASHINGTON — Executives of Emergent BioSolutions, the Covid-19 vacc...

ABC News Turn on desktop notifications for breaking stories about interest? OffOn Emergents spotty track record: What years of inspection reports show about firm tasked with helping make vaccine Inspection reports obtained by ABC News show a series of quality control issues. • 11 min read Johnson & Johnson manufacturer’s embattled history with the FDA ABC News’ Bob Woodruff examines the history of citations for Emergent Biosolutions, which was forced to pause new production of a key ingr...

Emergent BioSolutions Inc (EBS) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Emergent BioSolutions Inc (NYSE: EBS) Popular Searches Operator Thank you for standing by, and welcome to the Emergent BioSolutions First Quarter 2021 Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to Bob Burrows. Please go ahead.SPONSORED: 10 stocks we like better than Emergent B...

Dive Brief: Robert Kramer, the chief executive of embattled contract drug manufacturer Emergent Biosolutions, said Thursday he takes full responsibility for the error at his companys Baltimore plant that ruined millions of doses of Johnson & Johnsons coronavirus vaccine.  But the CEO pushed back against what he called "unfair criticism" of Emergent, describing the vaccine manufacturing task the company took on as "Herculean." Working with the U.S. government, Emergent had agreed to produce the...

); b.push("");for(var c=0;c "),b.push(a[c]),b.push(""+"script".toString()+">");b.push("");b.push("

In wake of Emergents vaccine problems, CEOs stock trades come under scrutiny Johnson & Johnson manufacturer’s embattled history with the FDA Replay Video UP NEXT For Emergent BioSolutions, Feb. 8 was a day to revel in their success -- at least as far as the public was concerned. Standing alongside Maryland Gov. Larry Hogan at their Baltimore-area plant, Emergent CEO Robert Kramer boasted about the biotech firms role as "one of the key suppliers" helping to produce two promising COVID-19 v...

SAUL LOEB/AFP via Getty Images (NEW YORK) -- For Emergent BioSolutions, Feb. 8 was a day to revel in their success -- at least as far as the public was concerned. Standing alongside Maryland Gov. Larry Hogan at their Baltimore-area plant, Emergent CEO Robert Kramer boasted about the biotech firms role as "one of the key suppliers" helping to produce two promising COVID-19 vaccines, and its "valuable contribution...

New details show a woman arrested on Friday as the suspected driver in a fatal wrong way crash that happened Feb. 10, may have been inebriated and had a previous DUI charge, according to Maricopa County Superior Court records. Court records show that Hannah Dike, who was arrested by the Arizona Department of Public Safety, tested with a blood alcohol level of 0.275% after the incident. They also state that Dike had been charged with a misdemeanor DUI in January 2019.  At 12:31 a.m. on F...

A new report from The Washington Post found that CEO Robert Kramer sold the stocks in January and early February, right before the price fell by more than 50% on February 19 after a financial report.

Apr 26, 2021 11:30am The head of Emergent BioSolutions sold more than $10 million in company shares earlier this year before prices began to slide. Emergent BioSolutions has faced a number of back-to-back PR crises since production issues at its Baltimore facility placed the company under intense scrutiny. The CDMOs stock price has tumbled as a result, but it appears CEO Robert Kramer cashed out some of his shares just in time.  Citing SEC filings, Kramer sold more than $10 million worth of...